Response to “Outdated Criteria for Drug Plan Reimbursement Obstruct Evidence-Based Care” Editorial in CMAJ

Abstract

The authors of an editorial published in CMAJ made 3 recommendations to incorporate new evidence into health technology assessments after the initial regulatory approval stage: incorporate automatic times for review or regular reviews of evidence, accept non-sponsor submissions, and audit prescribing for nonadherence to restricted drugs. This response to the editorial outlines existing and new evolving initiatives at CADTH to address each of the 3 recommendations.

Reimbursement decision-making system in Poland systematically compared to other countries

“…If the recommendation is negative, price negotiations can take place where the MAH can further demonstrate the cost-effectiveness of the therapy by lowering the price (Schwarzer and Siebert, 2009;Bending et al, 2012;Weise, 2018). In some countries, there are more institutions that have different functions and undertake HTA activities at the national level (Ireland, Germany, Sweden, Norway and Canada) (CADTH, 2021;Fontrier et al, 2022).…”

“…In England, HTA can be conducted as part of a multiple technology assessment-MTA (this is an assessment of several drugs or therapies used in one indication or one technology in several indications), as part of a single technology assessment-STA (technology assessment of one drug or therapy in one indication), or as part of fast technology assessment -FTA (this is used to provide patients with faster access to the most costeffective new treatments). In Norway, in addition to STA and MTA, a so-called mini HTA is used-a simplified assessment performed by clinical experts for in-hospital technologies (Gulácsi et al, 2012;CADTH, 2021).…”